Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 11/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1300912 | 0.86 | GAA (0.54) | CYP17A1CYP11B1CYP11B2CYP19A1CYP3A4 | |
| SCHEMBL11221372 | 0.82 | CYP17A1 (0.76) | CYP17A1CYP11B1CYP11B2CYP19A1CYP3A4 | |
| SCHEMBL7532192 | 0.82 | ALDH1A1 (0.58) | CYP17A1CYP11B1CYP11B2CYP19A1CYP3A4 | |
| SCHEMBL691933 | 0.81 | CALM1 (0.48) | CYP3A4RAB9APOLBKDM4EMEN1 | |
| SCHEMBL7433856 | 0.80 | CYP11B1 (0.45) | CYP11B1CYP11B2CYP3A4MEN1KMT2A | |
| SCHEMBL4011774 | 0.78 | CYP17A1 (0.59) | CYP17A1CYP11B1CYP11B2CYP19A1CYP3A4 | |
| SCHEMBL11229105 | 0.76 | CYP3A4 (0.77) | CYP17A1CYP11B1CYP11B2CYP19A1CYP3A4 | |
| SCHEMBL17737226 | 0.75 | CYP17A1 (0.56) | CYP17A1CYP11B1CYP11B2CYP19A1CYP3A4 | |
| SCHEMBL13873567 | 0.74 | CYP17A1 (0.65) | CYP17A1CYP11B1CYP11B2CYP19A1CYP3A4 | |
| SCHEMBL18770336 | 0.74 | CYP17A1 (1.00) | CYP17A1CYP11B1CYP11B2CYP19A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487797-B1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2009-05-27 | — | — | EP | disclosed |
| US-7144896-B2 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2006-12-05 | — | — | US | disclosed |
| US-20050245513-A1 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-11-03 | — | — | US | disclosed |
| EP-1487797-A1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078397-A1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-09-25 | — | — | WO | disclosed |
| EP-0834508-B1 | Substituted biphenyl or phenylpyridine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 2001-08-16 | — | — | EP | disclosed |
| US-5877190-A | PHOSPHODIESTERASE INHIBITOR | ADIR ET COMPAGNIE (FR) | 1999-03-02 | — | — | US | disclosed |
| CN-1202170-A | Quinoline derivatives as type 1V phosphodiesterase inhibitors | NOVARTIS AG (CH) | 1998-12-16 | — | — | CN | disclosed |
| EP-0873338-A1 | QUINOLINE DERIVATIVES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | Novartis AG (CH) | 1998-10-28 | — | — | EP | disclosed |
| EP-0691966-B1 | QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | SYNTEX INC (US) | 1998-09-09 | — | — | EP | disclosed |
| EP-0834508-A1 | Substituted biphenyl or phenylpyridine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1998-04-08 | — | — | EP | disclosed |
| WO-1997018208-A1 | QUINOLINE DERIVATIVES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | NOVARTIS AG (CH) | 1997-05-22 | — | — | WO | disclosed |
| EP-0691966-A1 | QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-01-17 | — | — | EP | disclosed |
| US-5455252-A | Antiinflammatory agent, immunosuppressant, antiallergen, skin disorders, bronchodilator, analgesic | SYNTEX (U.S.A.) INC. (US) | 1995-10-03 | — | — | US | disclosed |
| WO-1994022852-A1 | QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245513-A1 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | PDE4A, PDE4B, PDE4C | CYP17A1 1040/4885CYP11B1 796/4885CYP11B2 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.